Clinical Trials Directory

Trials / Completed

CompletedNCT02714816

Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65

Status
Completed
Phase
Study type
Observational
Enrollment
37 (actual)
Sponsor
MeiraGTx UK II Ltd · Industry
Sex
All
Age
3 Years
Healthy volunteers
Not accepted

Summary

MGT005 is a natural history study to collect longitudinal prospective data from patients with Leber Congenital Amaurosis associated with defects in RPE65.

Detailed description

Leber Congenital Amaurosis (LCA) is a diagnosis for a group of severe, autosomal recessively inherited rod - cone dystrophies that typically result in complete visual loss in the third or fourth decade of life. One form, LCA2, is caused by a mutation in the gene encoding RPE56, an RPE-specific 65-kDa isomerase. Non-functional RPE65 results in photoreceptor cells that are unable to respond to light resulting in these patients being visually impaired. In preparation for human clinical trials, a detailed prospective phenotypic study will be undertaken to investigate the natural history of RPE65-LCA. Such a study will help identify suitable patients for therapeutic intervention. Furthermore through greater phenotyping an optimal window for intervention and specific parameters to help quantify effect and identify clinical end points may have been ascertained .

Conditions

Timeline

Start date
2016-04-01
Primary completion
2023-07-22
Completion
2023-07-22
First posted
2016-03-22
Last updated
2023-08-14

Locations

2 sites across 2 countries: United States, United Kingdom

Source: ClinicalTrials.gov record NCT02714816. Inclusion in this directory is not an endorsement.